Sunshine Biopharma Inc. - Common stock (SBFM)

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.

SBFM stock results show that Sunshine Biopharma missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

A good rating for growth in the Portfolio Grader doesn't tell the full picture. These are all growth stocks to avoid now.

The best penny stocks to buy are those you can understand and stomach the exceptional risks of in order to profit.

SBFM stock results show that Sunshine Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Looking for the best meme stocks to sell after the Roaring Kitty rally? These three struggling companies seem to be beyond hope.